Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma - Trial NCT06053658
Access comprehensive clinical trial information for NCT06053658 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 2
Jan 31, 2024
Nov 01, 2028
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Summary
To learn if giving tivozanib in combination with nivolumab can help to control advanced
 nccRCC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06053658
Non-Device Trial